Literature DB >> 3884029

The biological and clinical significance of HCG-containing cells in seminoma.

D N Butcher, W M Gregory, P A Gunter, J R Masters, M C Parkinson.   

Abstract

The morphological appearance, incidence and prognostic significance of human chorionic gonadotrophin (HCG)-containing cells in seminomas were examined in a retrospective series of 228 orchidectomy specimens, obtained between 1958 and 1972. Sections from each tumour were stained with haematoxylin and eosin (H & E) and immunocytochemically for HCG. In 33 (14.5%) of the tumours HCG-containing cells were observed, but in only 12 were these recognised in an initial study of the H & E stained sections. HCG staining was seen predominantly in syncytiotrophoblastic giant cells and rarely in "mulberry" cells and mononuclear seminoma cells. Of the patients whose tumours included HCG-containing cells 23% died of their disease within 2 years of orchidectomy, compared with only 8% of the patients whose tumours lacked this feature. It is concluded that immunocytochemical staining for HCG should form part of the routine histological assessment of seminomas, and that the presence of HCG-containing cells indicates a more aggressive disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3884029      PMCID: PMC1977133          DOI: 10.1038/bjc.1985.68

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Malignant germ cell tumors of the ovary and testis. An immunohistologic study of 69 cases.

Authors:  R J Kurman; P T Scardino; K R McIntire; T A Waldmann; N Javadpour; H J Norris
Journal:  Ann Clin Lab Sci       Date:  1979 Nov-Dec       Impact factor: 1.256

2.  The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes.

Authors:  L A Sternberger; P H Hardy; J J Cuculis; H G Meyer
Journal:  J Histochem Cytochem       Date:  1970-05       Impact factor: 2.479

3.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Authors:  R Peto; M C Pike
Journal:  Biometrics       Date:  1973-09       Impact factor: 2.571

4.  Prognostic and therapeutic implications of urinary gonadotropin levels in the management of testicular neoplasia.

Authors:  J M Wilson; D M Woodhead
Journal:  J Urol       Date:  1972-11       Impact factor: 7.450

5.  Proceedings: Radiation therapy in malignant testis tumors. II: Carcinoma.

Authors:  J G Maier; M H Sulak
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

6.  Justification of the use of surveillance in the management of Stage I germ cell tumours of the testis.

Authors:  R T Oliver; H F Hope-Stone; J P Blandy
Journal:  Br J Urol       Date:  1983-12

7.  Letter: Syncytiotrophoblasts in malignant testicular tumours.

Authors:  E Heyderman; A M Neville
Journal:  Lancet       Date:  1976-07-10       Impact factor: 79.321

8.  The endocrinology of human chorionic gonadotropin-secreting testicular tumors: new methods in diagnosis.

Authors:  J S Cochran; P C Walsh; J C Porter; T C Nicholson; J D Madden; P C Peters
Journal:  J Urol       Date:  1975-10       Impact factor: 7.450

9.  Seminoma with syncytiotrophoblastic giant cells. A special form of seminoma.

Authors:  C Hedinger; A R von Hochstetter; B Egloff
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1979-07-27

10.  Human chorionic gonadotropin (HCG) and alpha-fetoprotein (AFP) in sera and tumor cells of patients with testicular seminoma: a prospective study.

Authors:  N Javadpour; K R McIntire; T A Waldmann
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

View more
  9 in total

Review 1.  Seminoma testis with elevated serum beta-HCG--a category of germ-cell cancer between seminoma and nonseminoma.

Authors:  K P Dieckmann; W Düe; H W Bauer
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

2.  Findings in lymph nodes of patients with germ cell tumours after chemotherapy and their relation to prognosis.

Authors:  R J Zuk; B J Jenkins; J E Martin; R T Oliver; S I Baithun
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

3.  HLA-antigen distribution in seminoma, HCG-positive seminoma and non-seminomatous tumours of the testis.

Authors:  C Kratzik; P Aiginger; R Kuzmits; J Spona; M Kirnbauer; A Seiser; W R Mayr
Journal:  Urol Res       Date:  1989

Review 4.  [Testicular tumours from a clinical point of view : What urologists and oncologists need to know from the pathologist about testicular cancer].

Authors:  Christoph Oing; Christian Daniel Fankhauser
Journal:  Pathologie (Heidelb)       Date:  2022-09-26

5.  Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry: serum protein profiling in seminoma patients.

Authors:  Romy Strenziok; Stefan Hinz; Christian Wolf; Tim Conrad; Hans Krause; Kurt Miller; Mark Schrader
Journal:  World J Urol       Date:  2009-06-16       Impact factor: 4.226

Review 6.  [What does the oncologist need from the pathologist in testicular cancer?]

Authors:  Christoph Oing; Mia-Carlotta Peters; Felix Bremmer
Journal:  Pathologe       Date:  2020-12       Impact factor: 1.011

7.  Testis cancer incidentally found following delayed presentation of traumatic testicular rupture.

Authors:  Jillian R Scambia; Sarah P Psutka
Journal:  Urol Case Rep       Date:  2017-10-14

8.  DNA hypomethylation and aberrant expression of the human endogenous retrovirus ERVWE1/syncytin-1 in seminomas.

Authors:  Martina Benešová; Kateřina Trejbalová; Denisa Kovářová; Zdenka Vernerová; Tomáš Hron; Dana Kučerová; Jiří Hejnar
Journal:  Retrovirology       Date:  2017-03-17       Impact factor: 4.602

Review 9.  Testicular Germ Cell Tumours and Proprotein Convertases.

Authors:  Aitziber Velado-Eguskiza; Laura Gomez-Santos; Iker Badiola; Francisco José Sáez; Edurne Alonso
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.